Jump to main content
Jump to site search

Issue 8, 2013
Previous Article Next Article

Prospective use of molecular field points in ligand-based virtual screening: efficient identification of new reversible Cdc25 inhibitors

Author affiliations

Abstract

A series of novel reversible inhibitors of the dual-specificity phosphatase Cdc25 was discovered using a two-stage molecular field-based similarity analysis. This method compares molecules on the basis of electrostatic and steric features, rather than their underlying structures, facilitating scaffold-hopping to new chemotypes. In this prospective study, a field point pharmacophore model was generated from three structurally diverse, reversible Cdc25 inhibitors and used in field-based virtual screening of 3.7 million commercially available compounds. Seven thiazoles, from the small set of 35 compounds selected for testing, showed reversible inhibition of activity at all three isoforms of Cdc25 (Cdc25A, B and C) at micromolar concentrations. The new series are not structurally related to the initial three starting points, but share their biological properties. Substructure searching rapidly identified additional thiazoles with modest (10-fold) increases in activity equivalent to those of the initial three starting points. This study demonstrates the effectiveness of this ligand-based method to both define a pharmacophore and effect virtual screening resulting in rapid and efficient identification of chemical starting points for development of novel therapeutic agents.

Graphical abstract: Prospective use of molecular field points in ligand-based virtual screening: efficient identification of new reversible Cdc25 inhibitors

Back to tab navigation

Supplementary files

Publication details

The article was received on 12 Feb 2013, accepted on 29 May 2013 and first published on 31 May 2013


Article type: Concise Article
DOI: 10.1039/C3MD00047H
Citation: Med. Chem. Commun., 2013,4, 1148-1155
  •   Request permissions

    Prospective use of molecular field points in ligand-based virtual screening: efficient identification of new reversible Cdc25 inhibitors

    J. C. Collins, A. Armstrong, K. L. Chapman, H. C. Cordingley, A. A. Jaxa-Chamiec, K. E. Judd, D. J. Mann, K. A. Scott, C. J. Tralau-Stewart and C. M. R. Low, Med. Chem. Commun., 2013, 4, 1148
    DOI: 10.1039/C3MD00047H

Search articles by author

Spotlight

Advertisements